New Jersey biotech nets $50M+ BARDA contract for respiratory candidate
Eagle Pharmaceuticals is keeping an eye on Enalare Therapeutics’ lead respiratory candidate, and apparently, so is the US government.
The New Jersey-based biotech struck a deal with BARDA worth up to $50.3 million to develop the lead compound, dubbed ENA-001, the company announced on Tuesday. The candidate is designed to simulate breathing and is meant to be used in emergency cases when treating drug overdoses or respiratory depression post-surgery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.